<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2836">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459693</url>
  </required_header>
  <id_info>
    <org_study_id>070129</org_study_id>
    <secondary_id>07-M-0129</secondary_id>
    <nct_id>NCT00459693</nct_id>
  </id_info>
  <brief_title>PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)</brief_title>
  <official_title>PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using (11C)PBR28 in HIV-Seropositive Patients With (MCMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to measure a receptor in the brain using positron emission&#xD;
      tomography (PET) that is involved in inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The peripheral benzodiazepine receptor (PBR) is distinct from central benzodiazepine&#xD;
      receptors associated with GABAa receptors. Although PBR was initially identified in&#xD;
      peripheral organs such as kidneys, endocrine glands and lungs, later studies identified PBR&#xD;
      in the central nervous system. In normal conditions, PBR is expressed in low levels in some&#xD;
      neurons and glial cells. PBR can be a clinically useful marker to detect neuroinflammation,&#xD;
      because activated microglial cells in inflammatory areas express much greater levels of PBR&#xD;
      than in microglial cells in resting conditions.&#xD;
&#xD;
      PBR has been imaged with positron emission tomography (PET) using&#xD;
      [11C]1-(2-chlorophenyl-N-methylpropyl)-3-isoquinoline carboxamide (PK11195). However, this&#xD;
      classical ligand provides low levels of specific signal. Recently we developed a new ligand,&#xD;
      N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine [11C]PBR28, which showed much greater&#xD;
      specific signal than [11C]PK11195 in non-human primates. ln the present protocol we plan to&#xD;
      perform a kinetic brain imaging study with [11C]PBR28 in HlV-seronegative controls,&#xD;
      HIV-seropositive, non-impaired patients, and HlV-seropositive patients with minor cognitive&#xD;
      motor disorder(MCMD). Each subject will recieve a brain-dedicated PET scan with 20&#xD;
      mCi[(11)C]PBR28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 9, 2007</start_date>
  <completion_date type="Actual">April 6, 2014</completion_date>
  <primary_completion_date type="Actual">April 6, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Brain uptake of [11C]PBR28 (measured as distribution volume).</measure>
    <time_frame>One brain PET scan in one outpatient visit to NIH per subject.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV-Dementia</condition>
  <condition>HIV-Associated Cognitive Motor Complex</condition>
  <condition>AIDS Encephalopathy</condition>
  <condition>AIDS Dementia Complex</condition>
  <condition>AIDS-Related Dementia Complex</condition>
  <condition>HIV Infections</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]PBR28</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Inclusion criteria (healthy control subjects) aged 18 50 years with history/physical exam,&#xD;
        ECG, and laboratory tests, plus inclusion criteria listed will be included in the protocol.&#xD;
&#xD;
          1. HIV-seropositive based on ELISA and Western blot (except the HIV-seronegative&#xD;
             subjects, who will have ELISA screening).&#xD;
&#xD;
          2. Capable of providing informed consent.&#xD;
&#xD;
          3. Ambulatory at initial visit.&#xD;
&#xD;
          4. If cognitively impaired, the degree of impairment will be MCMD, and not frank&#xD;
             HIV-associated dementia.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Current psychiatric illness or severe systemic disease based on history and physical&#xD;
             exam&#xD;
&#xD;
          2. Current dependence on alcohol or substances other than nicotine.&#xD;
&#xD;
          3. Laboratory results from blood or urine tests that show clinically significant&#xD;
             abnormalities.&#xD;
&#xD;
          4. Previous radiation exposure (X-rays, PET scans etc.) that would exceed research&#xD;
             limits.&#xD;
&#xD;
          5. Pregnancy and breast feeding.&#xD;
&#xD;
          6. A history of brain disease.&#xD;
&#xD;
          7. Cannot lie on your back for long periods since the pictures will be taken for about&#xD;
             2.5 hours during which time you will have to lie still on the scanner bed.&#xD;
&#xD;
          8. More than moderate hypertension.&#xD;
&#xD;
          9. Positive result on urine screen for illicit drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William C Kreisl, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson E, Zink W, Xiong H, Gendelman HE. HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr. 2002 Oct 1;31 Suppl 2:S43-54. Review.</citation>
    <PMID>12394782</PMID>
  </reference>
  <reference>
    <citation>Anholt RR, De Souza EB, Oster-Granite ML, Snyder SH. Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther. 1985 May;233(2):517-26.</citation>
    <PMID>2987488</PMID>
  </reference>
  <reference>
    <citation>Amodio P, Wenin H, Del Piccolo F, Mapelli D, Montagnese S, Pellegrini A, Musto C, Gatta A, Umilt√† C. Variability of trail making test, symbol digit test and line trait test in normal people. A normative study taking into account age-dependent decline and sociobiological variables. Aging Clin Exp Res. 2002 Apr;14(2):117-31.</citation>
    <PMID>12092785</PMID>
  </reference>
  <verification_date>August 28, 2014</verification_date>
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2007</study_first_posted>
  <disposition_first_submitted>September 3, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 3, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 10, 2020</disposition_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-Dementia</keyword>
  <keyword>Brain</keyword>
  <keyword>PET</keyword>
  <keyword>PBR28</keyword>
  <keyword>MCMD</keyword>
  <keyword>HIV Positive</keyword>
  <keyword>HIV Dementia</keyword>
  <keyword>AIDS Related Dementia</keyword>
  <keyword>Minor Cognitive Motor Disorder</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
    <mesh_term>AIDS Dementia Complex</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

